Navigation Links
Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS)

s a disease modifying treatment for multiple sclerosis (MS). Active Biotech developed laquinimod and licensed it to Teva Pharmaceutical Industries, Ltd. in June 2004. A previous 24-week Phase IIa trial conducted by Active Biotech demonstrated that oral 0.3 mg laquinimod given daily was well tolerated and reduced the formation of active lesions in RRMS. To date, 460 MS patients have received laquinimod in various clinical trials.

About MS

Multiple Sclerosis (MS) is the leading cause of neurological disability in young adults. It is estimated that 400,000 people in the United States are affected by this disease, and that over one million people are affected worldwide. MS is a progressive, demyelinating disease of the central nervous system affecting the brain, spinal cord and optic nerves.

Patients with MS may experience physical symptoms and/or cognitive impairments, including weakness, fatigue, ataxia, physical dysfunction, bladder and bowel problems, sensory effects, and visual impairment. MS also has a significant impact on the sufferers' social functioning and overall quality of life.

About Teva

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA), headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the leading generic pharmaceutical company. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products. Close to 90 percent of Teva's sales are in North America and Europe. Teva's innovative R&D focuses on developing novel drugs for diseases of the central nervous system.

About Active Biotech

Active Biotech AB (ACTI.ST) is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
2. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
3. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
4. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
5. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
6. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
7. Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study
8. Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory Compound, Shows Efficacy in Psoriasis
9. Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Societys Annual Meeting
10. Encouraging Clinical Activity of GSKs Novel Cancer Immunotherapeutic Confirmed in Phase II Study in Patients with Most Common Form of Lung Cancer
11. Clinical Data on ARIADs Novel mTOR Inhibitor, AP23573, To Be Presented at the ASCO Annual Meeting
Post Your Comments:
(Date:9/1/2015)... --  Alpha Imaging LLC , a leading distributor of advanced medical ... that they have been awarded exclusive rights to represent the complete ... new territory supplements Alpha Imaging,s existing Shimadzu sales and service responsibilities ... , Indiana , Pennsylvania , ... West Virginia , Delaware and ...
(Date:9/1/2015)... BAKERSFIELD, Calif. , Sept. 1, 2015 /PRNewswire/ ... Chronic Care Management (CCM) and Drug Adherence m ... monitoring help automate the process of non face-to-face ... "With this new release of our apps, ... care management services along with our ONCHIT certified ...
(Date:9/1/2015)... , Sept. 1, 2015 Within ... employees, SHL Group has rapidly reached 3,000 employees ... rapid growth in the injectable drug delivery market ... A global leader in the design and ... offers innovative designs, robust manufacturing capabilities, a lean ...
Breaking Medicine Technology:Alpha Imaging Expands Shimadzu Territory 2SPAC International's Drug Adherence and Chronic Care Management App Now available at Apple App and Google Play stores 2SHL Group Reaches Major Milestone of 3000 Employees 2
... WIRE)--Jun 4, 2007 - Cytogen Corporation,(NASDAQ: CYTO) ... QUADRAMET (samarium Sm-153 lexidronam injection),can be safely ... also,receiving the chemotherapy docetaxel (Taxotere(R), Sanofi-Aventis).,Clinical data ... for the treatment of prostate cancer in ...
... 2007 /PRNewswire-FirstCall/ -- VION,PHARMACEUTICALS, INC. announced that it ... the 43rd Annual Meeting of The American,Society of ... (VNP40101M) as a single agent in a Phase ... cell lung cancer. , The Phase II trial ...
Cached Medicine Technology:New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting 2New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting 3New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting 4New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting 5New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting 6New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting 7Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II,trial of Cloretazine (VNP40101M) in Patients with Relapsed or,Refractory Small Cell Lung Cancer 2Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II,trial of Cloretazine (VNP40101M) in Patients with Relapsed or,Refractory Small Cell Lung Cancer 3Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II,trial of Cloretazine (VNP40101M) in Patients with Relapsed or,Refractory Small Cell Lung Cancer 4
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... PAYROLL FITNESS" and will provide two days of payroll education covering legislative updates, ... technology changes. The speakers, which include representatives from Ceridian, Ultimate Software, the American ...
(Date:9/2/2015)... ... September 02, 2015 , ... This Fall, as ... (BCAM), Bright Pink, a national non-profit focused on the prevention and early detection ... a campaign to educate women to be breast and ovarian self-aware and celebrate ...
(Date:9/1/2015)... ... ... men, the first thing they notice when they go to button their white collar shirt ... with a collar that doesn’t close against the skin, creating a sloppy look. Or men ... because it’s uncomfortable. Now men in suits will be able to do something about ...
(Date:9/1/2015)... ... September 01, 2015 , ... Earth Brands, ( http://www.earthbrands.com ... collection. Every customer who buys an Earth Brand shoe will be given an ... Trees for the Future, a nonprofit dedicated to planting more trees. Earth Brands ...
(Date:9/1/2015)... San Diego, CA (PRWEB) , ... September 01, 2015 , ... ... with Bellus Academy will present “The Beauty Behind the Fashion” on Thursday, Oct. ... San Diego® (FWSD), will shine the spotlight on the collaboration between fashion and professional ...
Breaking Medicine News(10 mins):Health News:23rd Annual NJ Statewide Payroll Conference in Vernon, NJ at the Minerals Hotel on October 15-16, 2015 2Health News:Bright Pink Launches Act On Facts™, A Campaign To Empower Young Women To Take Action Related To Their Breast And Ovarian Health 2Health News:Bright Pink Launches Act On Facts™, A Campaign To Empower Young Women To Take Action Related To Their Breast And Ovarian Health 3Health News:Getting Rid of Double Chins: New FDA Approved Kybella Treatment Proving Very Popular Among Professional Men at Crutchfield Dermatology 2Health News:Earth Brands Footwear Partners with Trees for the Future for Launch of Fall Collection: Buy Shoes, Plant a Tree 2Health News:Earth Brands Footwear Partners with Trees for the Future for Launch of Fall Collection: Buy Shoes, Plant a Tree 3Health News:Celebrity Hairstylist Ted Gibson Explores Fusion of Fashion and Beauty at “Beauty Behind the Fashion” at Fashion Week San Diego Proceeds to benefit THIRST Project 2Health News:Celebrity Hairstylist Ted Gibson Explores Fusion of Fashion and Beauty at “Beauty Behind the Fashion” at Fashion Week San Diego Proceeds to benefit THIRST Project 3
... helps reduce the risk of reactivating the hepatitis B ... for breast cancer.An estimated 12 percent // of breast ... patients are at risk of developing HBV reactivation during ... degrees of liver damage that may lead to death. ...
... Most men with prostate cancer would rather find out sooner ... tested for prostate cancer using the prostate-specific antigen test. But since ... // for doctors to know what a high reading is and ... with higher levels have to undergo repeated biopsies to determine whether ...
... disease is a genetic disease that occurs predominantly in people ... from blood vessels being blocked by red blood cells // ... High blood pressure in the lungs is known as pulmonary ... pressure measured by a cuff on your arm. Instead, pulmonary ...
... study sheds light on the theory that aging is associated ... suggest the gene responsible for shortening the ends of chromosomes ... measured the length of the end of the chromosomes, known ... random sample of families living in northern Belgium. Telomere length ...
... the University of Chicago ( an evolution specialist ), ... The consortium's research, genetically fingerprinted virus samples from several ... Kong.// ,The work provides more evidence that SARS ... suggests, that prompt control of new cases is crucial, ...
... for kids in the United Kingdom, finds a new ... preschoolers. ,The study involved 78 children who were 3 ... their total energy expenditure, along with their amount of ... were spending only about 20 to 25 minutes a ...
Cached Medicine News:Health News:Reducing The Risk Of Death In Sickle Cell Disease 2Health News:Scientists Have Traced How The SARS Virus evolved 2
... Faster speeds, highest precision, more user-friendliness and ... this is the definition of the Mastercycler ... nucleic acid research has been developing dynamically. ... of PCR Systems. To keep pace ...
... Thermal Cycler is one of the smallest ... Benefits include: Fast ramping, low cost, ... and program naming, Ready-to-go templates, interchangeable blocks. ... Biology and Diagnostic laboratories and is suitable ...
MiniCycler thermal cycler with Hot Bonnet heated lid, holds 16x0.5ml tubes...
... The DNA Engine instrument is the ... uniformity and swappable blocks ensure consistent results, ... more than just a cycler, it's a ... research needs evolve. DNA Engine thermal cycler ...
Medicine Products: